Candel Therapeutics Inc (CADL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Candel Therapeutics Inc (CADL) has a cash flow conversion efficiency ratio of -0.128x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.24 Million) by net assets ($80.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Candel Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Candel Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Candel Therapeutics Inc for a breakdown of total debt and financial obligations.
Candel Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Candel Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tsogo Sun
JSE:TSG
|
0.196x |
|
Gospell Digital Technology Co Ltd
SHE:002848
|
-0.071x |
|
DAKOTA GOLD CORP. DL-001
F:RR6
|
N/A |
|
Fujian Jinsen Forestry Co Ltd
SHE:002679
|
-0.009x |
|
Vigil Neuroscience Inc
NASDAQ:VIGL
|
-0.496x |
|
E. W. Scripps Co Class A
NASDAQ:SSP
|
0.036x |
|
GEM Services Inc
TW:6525
|
0.071x |
|
EVN Finance JSC
VN:EVF
|
-0.339x |
Annual Cash Flow Conversion Efficiency for Candel Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Candel Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see CADL market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $66.33 Million | $-27.02 Million | -0.407x | +84.84% |
| 2023-12-31 | $12.74 Million | $-34.24 Million | -2.687x | -308.04% |
| 2022-12-31 | $47.71 Million | $-31.42 Million | -0.658x | -90.09% |
| 2021-12-31 | $64.14 Million | $-22.22 Million | -0.346x | -189.98% |
| 2020-12-31 | $-23.56 Million | $-9.07 Million | 0.385x | -40.23% |
| 2019-12-31 | $-8.04 Million | $-5.18 Million | 0.644x | -- |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developin… Read more